MEDINET Co., Ltd.

Equities

2370

JP3920990003

Biotechnology & Medical Research

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-26 am EDT			5-day change	1st Jan Change
45 ^JPY	0.00%		0.00%	+4.65%

2023	MEDINET Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending September 30, 2024	CI
2023	Kokoro Mill Co., Ltd announced that it has received ¥270 million in funding from MEDINET Co., Ltd., Macnica, Inc., Nahato Inc. and other investors.	CI

MEDINET Co., Ltd. Provides Earnings Guidance for the Year Ending September 30, 2023

February 09, 2023 at 01:00 am EST

MEDINET Co., Ltd. provided earnings guidance for the year ending September 30, 2023. For the year ending September 30, 2023, the company expects net sales of JPY 728 million, operating loss of JPY 1,766 million and loss of JPY 1,761 million or JPY 8.32 per basic share.

Latest news about MEDINET Co., Ltd.

MEDINET Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending September 30, 2024	Nov. 10	CI
Kokoro Mill Co., Ltd announced that it has received ¥270 million in funding from MEDINET Co., Ltd., Macnica, Inc., Nahato Inc. and other investors.	23-09-18	CI
Kokoro Mill Co., Ltd announced that it expects to receive funding from MEDINET Co., Ltd.	23-08-27	CI
MEDINET Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending September 30, 2023	23-07-31	CI
MEDINET Co., Ltd. announced that it has received ¥33.075 million in funding from Macquarie Bank Limited, Investment Arm	23-03-05	CI
MEDINET Co., Ltd. announced that it expects to receive ¥33.075 million in funding from Macquarie Bank Limited, Investment Arm	23-02-16	CI
MEDINET Co., Ltd. Provides Earnings Guidance for the Year Ending September 30, 2023	23-02-09	CI
MEDINET Co., Ltd. Provides Earnings Guidance for the Year Ending September 30, 2023	22-11-11	CI
Medinet Co., Ltd. Provides Earnings Guidance for the Year Ending September 30, 2022	22-08-10	CI
MEDINET Co., Ltd. Provides Earnings Guidance for the Year Ending September 30, 2022	22-05-12	CI
MEDINET Co., Ltd. Provides Earnings Guidance for the Year Ending September 30, 2022	22-02-10	CI
MEDINET Co., Ltd. Provides Earnings Guidance for the Year Ending September 30, 2022	21-11-12	CI
MEDINET Co., Ltd. announced that it has received ¥22.44 million in funding from Macquarie Bank Limited, Investment Arm	21-08-31	CI
MEDINET Co., Ltd. announced that it expects to receive ¥22.44 million in funding from Macquarie Bank Limited, Investment Arm	21-08-15	CI
MEDINET Co., Ltd. Reports Earnings Results for the Third Quarter Ended June 2021	21-08-11	CI
Medinet Co., Ltd. Provides Earnings Guidance for the Year Ending September 30, 2021	21-08-11	CI
MEDINET Co., Ltd. Reports Earnings Results for the Second Quarter Ended March 2021	21-05-12	CI
MEDINET Co., Ltd. Provides Earnings Guidance for the Year Ending September 2021	21-05-12	CI
MEDINET Co., Ltd. Reports Consolidated Earnings Results for the First Quarter Ended December 31, 2020	21-02-05	CI
MEDINET Co., Ltd. Provides Earnings Guidance for the Year Ending September 30, 2021	21-02-05	CI
Medinet Co., Ltd. Reports Consolidated Earnings Results for the Year Ended September 30, 2020	20-11-13	CI
MEDINET Co., Ltd. Provides Earnings Guidance for the Year Ending September 30, 2021	20-11-13	CI
MEDINET Co., Ltd.(TSE:2370) added to S&P Global BMI Index	20-09-21	CI
MEDINET Co., Ltd. announced that it has received ¥24.13 million in funding from Macquarie Bank Limited, Investment Arm	20-09-06	CI
MEDINET Co., Ltd. announced that it expects to receive ¥24.13 million in funding from Macquarie Bank Limited, Investment Arm	20-08-20	CI

Chart MEDINET Co., Ltd.

Duration

Period

More charts

Company Profile

MEDINET Co., Ltd. is a Japan-based company mainly engaged in cell processing industry and cellular medical products business. It operates through two business segments. The Cell Processing Industry segment mainly engages in comprehensive support services for immune cell therapy, related services including clinical use from companies, universities, research institutes, outsourcing of cell processing for clinical trials and operation of cell culture processing facilities. The Cellular Medical Products segment is mainly engaged in research and development for obtaining approval for manufacture and marketing of cellular medical products. It also provides comprehensive support services for immune cell therapy.

Sector

Biotechnology & Medical Research

Calendar

2024-05-09 - Q2 2024 Earnings Release

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MEDINET CO., LTD.	+4.65%	73.24M
IQVIA HOLDINGS INC.	+1.51%	42.75B
MODERNA, INC.	+8.57%	41.34B
LONZA GROUP AG	+49.22%	41.61B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research